BI/OND on lifesciencesatwork.nl

BI/OND on lifesciencesatwork.nl

BIOND Mission

Become the hardware of choice for OOC in-vitro testing of drug candidates, reducing the incidence of false positives and false negative in pre-clinical trials.


Executive Summary

Organ-on-Chips (OOCs) are micro-fluidics devices designed to simulate in vivo human physiology by promoting cell and tissue growth in vitro. Pharmaceutical companies are heralding the development of these dynamic systems to replace the traditional and static cell-based assays in order to reduce the false positives and negatives during pre-clinical drug testing.

Currently, there is no OOC on the market that fulfills simultaneously the three main needs of pharmaceutical companies: a better predictive model reducing the false positives and negatives, a comprehensive set of real-time data, all enclosed in an easy to use interface.

However, all these needs can be satisfied through BIOND’s novel hardware. With its proprietary technology, BIOND will offer an innovative microfluidic system for OOC applications able to address the above mentioned issues. BIOND’s technology consists of a microfluidic chip, called BiondChip, that is used in combination with a user-friendly well-plate, called BiondPlate. The system has the potential to mimic several organ functionalities used in toxicity and efficacy assays and disease modeling. BIOND will seek for partnerships to co-develop such models. The showcase obtained from these collaborations will validate the unique value of BIOND’s offer and will promote further alliances and product sales.

The main assets of BIOND include:

  • a unique and innovative patented technology for OOC applications with strong competitive advantages over currently marketed devices;
  • a skilled and motivated team with proven technological experience, supported by a biological network (hDMT) and the business expertise of the TU Delft valorisation center;
  • expertise in state-of-the-art polymer processing that can be applied for envisaged developments in a $31.5 million OCC market with 70% expected CAGR.

Watch the full article on www.lifesciencesatwork.nl